Association between testosterone replacement therapy and cardiovascular outcomes: A meta-analysis of 30 randomized controlled trials.
Prog Cardiovasc Dis
; 85: 45-53, 2024.
Article
en En
| MEDLINE
| ID: mdl-38589271
ABSTRACT
BACKGROUND:
The Cardiovascular safety of testosterone replacement therapy (TRT) among men with hypogonadism is not well established to date. Hence, we sought to evaluate the cardiovascular disease (CVD) outcomes among patients receiving testosterone therapy by using all recently published randomized controlled trials.METHODS:
We performed a systematic literature search on PubMed, EMBASE, and Clinicaltrial.gov for relevant randomized controlled trials (RCTs) from inception until September 30th, 2023.RESULTS:
A total of 30 randomized trials with 11,502 patients were included in the final analysis. The mean age was ranging from 61.61 to 61.82 years. Pooled analysis of primary and secondary outcomes showed that the incidence of any CVD events (OR, 1.12 (95%CI 0.77-1.62), P = 0.55), stroke (OR, 1.01 (95%CI 0.68-1.51), P = 0.94), myocardial infarction (OR, 1.05 (95%CI 0.76-1.45), P = 0.77), all-cause mortality (OR, 0.94 (95%CI 0.76-1.17), P = 0.57), and CVD mortality (OR, 0.87 (95%CI 0.65-1.15), P = 0.31) was comparable between TRT and placebo groups.CONCLUSION:
Our analysis indicates that for patients with hypogonadism, testosterone replacement therapy does not increase the CVD risk and all-cause mortality.Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Testosterona
/
Enfermedades Cardiovasculares
/
Ensayos Clínicos Controlados Aleatorios como Asunto
/
Terapia de Reemplazo de Hormonas
/
Hipogonadismo
Límite:
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Prog Cardiovasc Dis
Año:
2024
Tipo del documento:
Article